Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132663 · ClinicalTrials.gov registry record · NA
The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants
A NA study, sponsored by Mead Johnson Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 315
- Enrollment target
NCT02132663: Completed NA study, sponsored by Mead Johnson Nutrition.
NCT02132663 is a NA study that has completed, run by Mead Johnson Nutrition. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02132663, a NA study, has completed, sponsored by Mead Johnson Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
Study Summary
This clinical trial will evaluate an investigational infant formula with an alternate source of DHA to determine if it provides normal growth and if it is well tolerated by term infants as compared to a marketed routine infant formula.
Interventions
- OTHER Control: Marketed routine infant formula
- OTHER An investigational infant formula containing an alternate source of DHA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-04 |
| Phase | NA |
What the finished NCT02132663 record still lists
NCT02132663 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Control: Marketed routine infant formula is the first listed.
NCT02132663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02132663 about?
NCT02132663 is a clinical study titled "The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants". This clinical trial will evaluate an investigational infant formula with an alternate source of DHA to determine if it provides normal growth and if it is well tolerated by term infants as compared to a marketed routine infant formula.
What is the current status of trial NCT02132663?
This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2014-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02132663?
The interventions under investigation include: Control: Marketed routine infant formula (OTHER), An investigational infant formula containing an alternate source of DHA (OTHER).
Who is sponsoring clinical trial NCT02132663?
This trial is sponsored by Mead Johnson Nutrition, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02132663's enrollment target sits among peer trials
315 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia